FENC · XBRL financial data

Fennec Pharmaceuticals financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FENC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	200	—	1,535	21,252	47,538	44,642
Cost of goods and services sold	—	—	86	1,259	—	—
Gross profit	—	—	1,449	19,993	—	—
Research and development	5,105	4,981	3,531	56	307	250
General and administrative	12,950	12,242	17,722	20,585	23,053	28,294
Total operating expenses	18,055	17,223	24,038	32,764	44,970	50,924
Operating income (loss)	(17,885)	(17,223)	(22,589)	(12,771)	2,568	(6,282)
Interest income	—	—	—	441	1,682	787
Interest expense	—	—	—	3,394	4,069	2,080
Other income (expense)	(9)	—	—	—	—	—
Income tax expense (benefit)	0	0	0	—	365	106
Net income (loss)	(18,109)	(17,346)	(23,714)	(16,045)	(436)	(9,741)
Earnings per share, basic USD per share	(0.76)	(0.67)	(0.90)	(0.60)	(0.02)	(0.34)
Earnings per share, diluted USD per share	(0.76)	(0.67)	(0.90)	(0.60)	(0.02)	(0.34)
Weighted average shares, basic thousands of shares	23,704	26	26,275	26,574	27,294	28,577
Weighted average shares, diluted thousands of shares	23,704	26	26,275	26,574	27,294	28,577

Fiscal years (FENC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	30,344	21,100	23,774	13,269	26,634	36,788
Total current assets	31,417	22,387	26,728	26,858	44,124	67,043
Total assets	31,417	22,414	26,939	26,864	44,946	70,551
Accounts payable	1,571	777	2,390	3,778	3,241	4,635
Accrued liabilities	776	877	2,219	3,754	3,428	5,635
Total current liabilities	2,347	1,654	4,609	7,553	6,919	10,518
Long-term debt	—	5,000	—	—	—	—
Lease liability, non-current	—	—	—	2	—	—
Total liabilities	2,347	6,642	29,508	38,486	50,818	35,079
Accumulated deficit	(162,140)	(179,486)	(203,200)	(219,245)	(219,681)	(229,422)
Total stockholders' equity	29,070	15,772	(2,569)	(11,622)	(5,872)	35,472
Total liabilities and equity	31,417	22,414	26,939	26,864	44,946	70,551
Common shares outstanding (cover page) thousands of shares	26,003	26,014	26,412	27,100	27,594	34,475

Fiscal years (FENC's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(18,109)	(17,346)	(23,714)	(16,045)	(436)	(9,741)
Stock-based compensation	2,791	3,749	4,087	5,354	5,061	7,033
Net cash from operating activities	(15,595)	(14,222)	(18,058)	(17,143)	26,980	(12,473)
Proceeds from issuing common stock	31,967	—	—	—	—	—
Proceeds from long-term debt	—	5,000	24,935	4,997	—	—
Repayments of long-term debt	—	—	5,000	—	13,000	19,477
Net cash from financing activities	32,289	4,978	20,732	6,638	(13,615)	22,627
Net change in cash	16,694	(9,244)	2,674	(10,505)	13,365	10,154

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.